Abstract: An information processing apparatus includes a processor programmed to: detect a request submitted from a terminal to an external server providing a service; and upon a determination that the detected request is submitted from the terminal located in a base, transmit a validation request for validating a certificate of the terminal to a CRL distribution server in which the certificate of the terminal is invalid.

Abstract: An information processing apparatus includes a processor configured to: in a network environment including plural individual networks, one or plural devices being connected to each of the plural individual networks, a user terminal being connected to one of the plural individual networks, determine plural route options, based on connecting information and configuration information, the connecting information indicating association between the user terminal and a connecting device, the connecting device being one of the plural devices and being a device to be connected and used by the user terminal, the configuration information indicating an individual network to which the user terminal is connected and indicating an individual network to which the connecting device is connected, the plural route options being options of routes which each connect the user terminal and the connecting device and which each include a repeater device that transfers data between the user terminal and the connecting device; select

Abstract: A communication apparatus is connected to a communication line by using a dynamically-set global Internet-Protocol address and includes a detector and a transmitting unit. The detector detects a change in the global Internet-Protocol address. The transmitting unit transmits the changed global Internet-Protocol address to a mail server when the detector detects the change in the global Internet-Protocol address, so that the changed global Internet-Protocol address is registered in an Internet-Protocol-address limiting function of the mail server.

Abstract: An information processing apparatus includes a processor programmed to: detect a request submitted from a terminal to an external server providing a service; and upon a determination that the detected request is submitted from the terminal located in a base, transmit a validation request for validating a certificate of the terminal to a CRL distribution server in which the certificate of the terminal is invalid.

Abstract: A communication apparatus is connected to a communication line by using a dynamically-set global Internet-Protocol address and includes a detector and a transmitting unit. The detector detects a change in the global Internet-Protocol address. The transmitting unit transmits the changed global Internet-Protocol address to a mail server when the detector detects the change in the global Internet-Protocol address, so that the changed global Internet-Protocol address is registered in an Internet-Protocol-address limiting function of the mail server.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: A computer readable medium stores a program causing a computer to execute a key generating processing. The computer generates a signatory private key which is used in an electronic signature, a signatory public key, a signatory public key certificate, a certification public key which is used when recording the signatory private key in a PKI card and a certification private key, transmits the certification private key to the PKI card via a secure communication path, and transmits an encoded signatory key obtained by encoding the signatory public key certificate and the signatory private key using the certification public key to the PKI card via the secure communication path or a non-secure communication path.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.

Abstract: An information processing system includes a signature apparatus and a signature verification apparatus which may be provided separately. The signature apparatus includes a document image generating unit and a print image generating unit. The document image generating unit generates a document image to be signed including document image data and error correction data for character images contained in the document image data. The print image generating unit synthesizes the document image and a code image to generate a print image. The signature verification apparatus includes a restoring unit that restores, from a print image, document image data included in a document image to be signed, using error correction data contained in the document image, and a signature verification unit that performs signature verification using the restored document image data and document image data included in a document image to be signed extracted from the print image.

Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.